kwic
significant
significant
right
off
ON
387
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for significant out of >500 occurrences
583352 occurrences (No.14 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to significant]
583352 occurrences (No.14 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 387) GS-9219, a novel prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethyl) guanine (PMEG) has significant activity as monotherapy in dogs with non-Hodgkin's lymphoma. |
| PMID:23672437 DOI:10.1111/vco.12038 |
| 2015 Veterinary and comparative oncology |
| * Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines. |
| - GS-9219, a novel prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethyl) guanine (PMEG) has significant activity as monotherapy in dogs with non-Hodgkin's lymphoma. Phase I trials have been initiated in humans based on the encouraging activity observed in canine lymphoma. Two new analogues of GS-9219 (GS-343074 and GS-424044) were recently produced for evaluation as potential novel antineoplastic agents against solid tumours. As a preclinical step, effect of GS-343074 and GS-424044 were evaluated against ten canine cancer cell lines for antiproliferative effect. Both analogues displayed antiproliferative activity against multiple canine cancer cell lines, although GS-343074 was more potent and of broader spectrum compared to GS-424044. Flow cytometric analysis of cells that experienced growth inhibition support apoptotic death as a mechanism of action for both analogues. On the basis of in vitro results described here, GS-343074 and GS-424044 show promise as novel anticancer agents in canine cancer. |
[
right
kwic]
(1)67  differences |
(15)5 correlations |
(29)3 influence |
(44)2 dose-dependent |
| (2)40 increase |
(16)5 effects |
(30)3 negative |
(45)2 elevation |
| (3)36 difference |
(17)5 for |
(31)3 number |
(46)2 evidence |
| (4)28 decrease |
(18)5 increases |
(32)3 roles |
(47)2 factors |
| (5)12 reduction |
(19)5 risk |
(33)2 (P |
(48)2 group |
| (6)11 predictors |
(20)4 effect |
(35)2 alterations |
(49)2 inhibition |
| (7)10 association |
(21)4 in |
(36)2 and |
(50)2 interaction |
| (8)9 improvement |
(22)4 reductions |
(37)2 at |
(51)2 morbidity |
| (9)8 *null* | (23)4 relationship |
(38)2 between-group |
(52)2 positive |
| (10)7 changes |
(24)3 (p |
(39)2 blood |
(53)2 prediction |
| (11)7 predictor |
(25)3 alteration |
(40)2 challenge |
(54)2 proportion |
| (12)7 role |
(26)3 as |
(41)2 contribution |
(55)2 source |
| (13)6 correlation |
(27)3 higher |
(42)2 cytotoxic |
(56)2 time |
| (14)5 associations |
(28)3 improvements |
(43)2 decreases |
add keyword
--- WordNet output for significant ---